Evidence map›Paper›PMID 24859531›Full record

ArticleNature medicine2014

The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma.

Chen Liu, Rachid Karam, YingQi Zhou, Fang Su, Yuan Ji, Gang Li, GuoTong Xu, LiXia Lu, ChongRen Wang, MeiYi Song and 9 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Nonsense-mediated mRNA decay: friend or foe in cancer biology?Cell communication and signaling : CCS · 2026
    Review
  5. [Research progress in clinical pathology and molecular mechanisms of pancreatic adenosquamous carcinoma].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Neoantigens: promising targets for cancer therapy.Signal transduction and targeted therapy · 2023
    Review

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 2 countries.

Chen Liu1] Clinical and Translational Cancer Research Center, The Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. [2] Tongji University School of Life Science and Technology, Shanghai, China. [3].
Rachid Karam1] Department of Reproductive Medicine, School of Medicine, University of California San Diego, La Jolla, California, USA. [2].
YingQi Zhou1] The Third General Surgery Department, Changhai Hospital, Second Military Medical University, Shanghai, China. [2].
Fang Su1] Clinical and Translational Cancer Research Center, The Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. [2].
Yuan Ji1] Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China. [2].
Gang LiThe Third General Surgery Department, Changhai Hospital, Second Military Medical University, Shanghai, China.
GuoTong XuClinical and Translational Cancer Research Center, The Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
LiXia LuClinical and Translational Cancer Research Center, The Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
ChongRen WangClinical and Translational Cancer Research Center, The Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
MeiYi SongClinical and Translational Cancer Research Center, The Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
JingPing ZhuClinical and Translational Cancer Research Center, The Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
YiRan WangClinical and Translational Cancer Research Center, The Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
YiFan ZhaoClinical and Translational Cancer Research Center, The Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Wai Chin FooDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
MingXin ZuoDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Mark A ValasekDivision of Anatomic Pathology, Department of Pathology, University of California San Diego, San Diego, California, USA.
Milind JavleDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Miles F Wilkinson1] Department of Reproductive Medicine, School of Medicine, University of California San Diego, La Jolla, California, USA. [2] Institute for Genomic Medicine, University of California San Diego, La Jolla, California, USA.
YanJun LuClinical and Translational Cancer Research Center, The Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Tongji University · CNThe University of Texas MD Anderson Cancer Center · USUniversity of California, San Diego · USChanghai Hospital · CNSecond Military Medical University · CNSun Yat-sen University · CN

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
TCR RNA SurveillanceR01GM058595 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WILKINSON, MILES FROME · 1999 to 2012
$4.1M
The Role of NMD in Olfactory NeurogenesisR01GM111838 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WILKINSON, MILES FROME · 2014 to 2017
$1.6M
NCI NIH HHS P30 CA016672NIGMS NIH HHS R01 GM058595NIGMS NIH HHS R01 GM111838
6 · The paper itself

Abstract

Pancreatic adenosquamous carcinoma (ASC) is an enigmatic and aggressive tumor that has a worse prognosis and higher metastatic potential than its adenocarcinoma counterpart. Here we report that ASC tumors frequently harbor somatically acquired mutations in the UPF1 gene, which encodes the core component of the nonsense-mediated RNA decay (NMD) pathway. These tumor-specific mutations alter UPF1 RNA splicing and perturb NMD, leading to upregulated levels of NMD substrate mRNAs. UPF1 mutations are, to our knowledge, the first known unique molecular signatures of pancreatic ASC.

Indexed as

Alternative SplicingBase SequenceCarcinoma, AdenosquamousGene ComponentsHEK293 CellsHumansImmunohistochemistryIn Situ Nick-End LabelingMolecular Sequence DataMutagenesisMutationNonsense Mediated mRNA DecayPancreatic NeoplasmsReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA HelicasesRNA HelicasesTrans-ActivatorsUPF1 protein, human

Identifiers

PMID24859531
PMCPMC4048332
OpenAlexW2151627051

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.